• About Us
    • Overview
    • Managament
    • Scientific Advisory Board
    • Supervisory Board
    • Collaborations
  • Our Research
    • Overview
    • Clinical Projects
    • Immunooncology
    • Synthetic Lethality
    • Collaborations
    • Publications
  • Pipeline
  • Investors & Media
  • Careers
    • Why work with is
    • Meet the company
    • About Cracow
    • Benefits
    • Recruitment Process
    • Job Offers
  • Contact Us
  • EN
  • PL

Report: Current Stock Reports

Title
  • Changes in Ryvu’s Management Board
    July 26, 2022

    Read More
  • Information on a potential supply of shares in connection with the expiration of the lock-up period for shares under the Stock Grant Program
    July 8, 2022

    Read More
  • Execution of an exclusive license agreement with Exelixis, Inc. to develop novel STING agonist-based targeted cancer therapies
    July 7, 2022

    Read More
  • Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 30, 2022
    July 1, 2022

    Read More
  • Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
    July 1, 2022

    Read More
  • Publication of the updated phase 1b clinical and preclinical data for RVU120 and phase 1/2 SEL24 (MEN1703)
    June 10, 2022

    Read More
  • Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
    June 3, 2022

    Read More
  • New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Hybrid Congress 2022
    May 12, 2022

    Read More
  • Ryvu Therapeutics to present recent RVU120 and SEL24 (MEN1703) data at ASCO 2022 Annual Meeting
    April 27, 2022

    Read More
  • Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
    April 1, 2022

    Read More

Posts navigation

Older posts
Contact Us
Ryvu Therapeutics [email protected] +48 12 297 46 90
Follow us
  • Privacy Policy
  • Cookies Policy
  • Sitemap
Copyright by Ryvu Therapeutics 2022